<SEC-DOCUMENT>0001213900-24-001715.txt : 20240108
<SEC-HEADER>0001213900-24-001715.hdr.sgml : 20240108
<ACCEPTANCE-DATETIME>20240108070006
ACCESSION NUMBER:		0001213900-24-001715
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240108
FILED AS OF DATE:		20240108
DATE AS OF CHANGE:		20240108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		24518255

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea191303-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>January 2024</B></P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>107 Cheapside</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="background-color: white"><B>EC2V 6DN</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="text-align: center; font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">x</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Form&nbsp;40-F&nbsp;</FONT><FONT STYLE="font-family: Wingdings">o</FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 8, 2024, Tiziana Life Sciences LTD
(the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, positive findings have been seen in a total of six out of eight Intermediate
Size Patient Population Expanded Access (EA) patients. These patients have shown improvements in fatigue scores measured by the Modified
Fatigue Impact Scale (MFIS). PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS
score improvement at the three-month evaluation period. PET scan findings for two additional EA patients (10 total) are planned to be
available in late January., a copy of which is furnished as Exhibit 99.1</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 4%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 5%">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 31%">&nbsp;</TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: January 8, 2024</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: normal 10pt Times New Roman, Times, Serif; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: normal 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="font: normal 10pt Times New Roman, Times, Serif; vertical-align: top"><A HREF="ea191303ex99-1_tiziana.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tiziana Life Sciences LTD Press Release, dated January 8, 2024</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: normal 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea191303ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JANUARY 8, 2024
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-size: 12pt">Tiziana Life
Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK,&nbsp;January 08, 2024 -- Tiziana Life Sciences Ltd.&nbsp;(Nasdaq:
TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough neuro-immunomodulation therapies,
today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access (EA)
patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale (MFIS). PET scan findings
showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation
period. PET scan findings for two additional EA patients (10 total) are planned to be available in late January.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Tarun Singhal, M.B.B.S., M.D., Director
of PET Imaging Program in Neurologic Diseases at Brigham and Women&rsquo;s Hospital, a founding member of Mass General Brigham Healthcare
System, and Associate Professor of Neurology at Harvard Medical School, commented, &ldquo;Upon review of the baseline and three-month
[F-18] PBR06 PET scans of the two new na-SPMS EA patients, a qualitative reduction in microglial activity was seen in one of two new patients.
When combined with my assessment of the first six EA patients at three-months, a total of six out of the eight suggested a reduction in
qualitative microglial PET signal. These findings are promising from an imaging standpoint and further studies are needed to confirm them
using additional quantitative approaches.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The EA patient having a qualitative improvement in their PET
scan also improved in their Modified Fatigue Impact Scale,&rdquo; stated Dr. Tanuja Chitnis, M.D., Principal Investigator and Professor
of Neurology at Harvard Medical School and senior neurologist at Brigham and Women&rsquo;s Hospital. &ldquo;Six out of the eight na-SPMS
EA patients studied so far have seen measurable clinical improvement in their fatigue. I am excited to lead the effort to replicate these
findings in the ongoing Phase 2 dose-ranging, randomized, placebo-controlled clinical trial.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life
Sciences noted &ldquo;We&rsquo;ve seen continued clinical and qualitative PET scan improvement over time in patients with na-SPMS where
intranasal foralumab targets inflammation in the brain. It is my expectation that we will rapidly progress our ongoing Phase 2 trial of
intranasal foralumab, given the encouraging results seen so far under the EA IND</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Foralumab</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Activated T cells
play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the
T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell
subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
The non-active SPMS intranasal foralumab Phase 2 trial dosed its first patient in December of 2023. Immunomodulation by nasal anti-CD3
mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT><SUP>,<FONT STYLE="font-size: 10pt">2</FONT></SUP></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT>
https://www.pnas.org/doi/10.1073/pnas.2220272120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>2</SUP></FONT>
https://www.pnas.org/doi/10.1073/pnas.2309221120</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About&nbsp;Tiziana Life Sciences</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: #FEFEFE">Tiziana Life Sciences&nbsp;is a clinical-stage
biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes
of immunotherapy. <FONT STYLE="font-size: 10pt">Tiziana&rsquo;s innovative nasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. </FONT>Tiziana&rsquo;s lead candidate, intranasal
foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in
studies to date. Tiziana&rsquo;s technology for alternative routes of immunotherapy has been patented with several applications pending
and is expected to allow for broad pipeline applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Forward-Looking Statements</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Certain statements made in this announcement
are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company&rsquo;s current
expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo;
&lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &lsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify forward-looking statements. These statements
are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are
beyond the Company&rsquo;s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted
in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance
on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Actual results may
differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties
related to market conditions and other factors described more fully in the section entitled &lsquo;Risk Factors&rsquo; in Tiziana&rsquo;s
Annual Report on Form 20-F for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission.
The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory
authority.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Paul Spencer, Business Development and
Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">Irina Koffler<BR>
LifeSci Advisors, LLC<BR>
+1 646 970 4681<BR>
ikoffler@lifesciadvisors.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B )8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^N7]N/X$?
MMP?%O1+IOV6/VK(/@] EDR3>!8O".EZ3J.LSK;LK26GQ:A35/$FBW$K-((;6
MST_3K<S/;R2:M9K:M)+_ !L?M-?LN_M>:/XRU3PY^TKXF^,&L^)5EEEF?X@>
M+/$OBN'4(YG)^V:;JFI:IJ=EJ>G7#;E@N]-NKFQ<K)#%*6B=$_37]MO]HK]L
M?_@E7^V_K/A+X9_%KQ5??LX_%I#\4OA?X&\=SOXW\&:)8:[J,J>+? NC0^)&
MU&ZT&S\+>*(;^&PT[P[?:4=/\,:IX<PZ2W&^OTD^ ?\ P4*^&?[:_AFV\!_M
M$_"WP_!JX$#V.O\ AR7=%;W=Q$\4FH:;8:X;F;26#K&ERAU^ZM[R&1HY[22%
M1 W[9PO2S+)LMHYBLKRO/\BJ4(XB>(R^EA<)GF$A)I3E4C6HN6,5&IS0K4W6
MG-<K=.I;E3_A?Q?S#(.*.**W#5+C3BOPWX_^OU,!@\%Q%7S;.?#_ #RM"#J4
M:-"O@<?&.15,=04:N!KQPE+#SE/V>(P\I<\U_(7HGP"\?^#[D7?A#7?$?AF]
M#!DN/#VI:IH]R)"<*5ETZ>WDWYX&UMV3ZBOZ'O\ @EG^P9^VM\4[W2?BY\?/
MVJ?VH?!GP!LYH+W0/ VF_&[XG:-K/Q6>WE1XXE,?B5)=#\!-L,=_J<"PWNNP
M%K'03##/)KMC^M^I_LM?LJ?!5H_B!XZLK7Q%IEBK:GIVA_8;.2&^,%P\<,<R
MW<\%O<VXDB:22U>Z?[8JRVSO<6=M=_VE^2'[?W_!8WXC/I.N?#WX$FW^%GA.
M.UGTB7Q!I$N_QAJ%ND:P>1INK+';1^&[/RU,42Z+96VIPKCRM8,),->GC,;5
MXMH2PG#&4T\-3MRX_/,VHX94L'3<G!TL'"6&J5ZV,D^=<T*=Z235-QJ<U:C\
MID>&K^#F98?,?%_C>KF^+JM/AGP^X+Q.;5<?GF)A%5OKN>XEYC2P& R2C&5&
M?)5Q$8XJ4Z<L2JM%T\#C/Z;?"GQ5^'?BOQKXW^&/A'Q)9Z_XI^%=MX>3QW8:
M=-)J">%;GQ$FHG1-'UC4MTL*Z]<6VCWMU<:8]Q+J-I;I%/J,<!N[?SORY_X*
MT_\ !7CPE_P2WB_9HBNOAUHGQAUKX]?&[0/AEKGAS_A:NC^ M:^'_@_589I;
MKXASV%SH/B2[U&SBDB:VLX[VWT/1IYXITN?$-HR*KX/_  0=^%VN>%?V+KCX
MM>+([P^)OVB?B1XF^(OVG47,E]/X8TUH?"?AV69WW2/%J%QHVM^(+61W8SVV
MNQ7/'G'/X4_\';/['_[/-QXU_87_ &C9/ .WXQ?&_P#:1\$_ 3XH>+8?$'B2
M+_A*?A;I.F2S:?H$VCKJIT2PN;7[9+%'K>EZ=9:P8 D4MY*L<>S\3S;!X? Y
MIC,#AJ\L31PE9X;ZQ)1BZU6E&$*]2,8MJ$'B/;*G'FDXPA%2E*3DS^[>$<VS
M+/.&,GSO-<#2RS&YMA(YB\NI3J5%@<-BZE6K@,-.K4C&=:O#+W@Y8FKR4HSK
MUJCITJ5-4X+^QH_M&_ JXT#QKXCT+XK^ _&=E\/?"&N>._%EGX \3Z/X]UW3
M?"_AVQGO]4U)?#WA&\UC6[L1PV[QV\%I8S7%[=M#96D4UW/#"_RC^QK_ ,%3
M_P!C_P#;<_9YUO\ :>^'?C/5OAG\)_#GQ)U/X4:SJ_[0VF6?P9-IXQTZSTK4
MHK2&]\2ZL?#VI6VK:=K6FW>EW&DZ[?%WFFTV\CLM:L-1TVT\1^ O_!&[_@GC
M_P $[)_BU\?OV1/@;>?"SXMS_!/XA^$(_&/_  LSXH^*KRQT*_T^/6[NVTVU
M\7^,=<T^PGEU/0-'N1?VUHE]$UC$L-Q&C2*_Y!_\&[W[,GP3_P""B?\ P1$T
MOX6?MK>#Y_VAO!%G^UU\6O%ECI?CKQ1XO>[L/$6DQ:1+8ZG9:YI6O:;KUK-'
M)XH\2/)'%J:V]RVNZHUS#*UY*6\VRLWK96]=;GTEW=+2[4GUMI:VN_X']-O_
M  V?^QY_T=?^S5_X?7X7?_-36MH/[6'[+/BK6M+\-^%_VE?@!XD\1:Y>P:;H
MN@:#\9/AUK&M:QJ-TXCMK#2]*T_Q'<7VH7MPY"06MI!-/*Y"QQL>*_CU_P""
MD_P&_P"#<+]A3Q#;? 'X9_L#6?[8'[<OBBY&B> OV3_@C\3OCMX@\01^)KO"
M:?:?$W6/#WC[6I/!D;L?/_X1VUL-7\>7MLHGM/#,.FROK-K3_P""7O\ P:XW
M.O\ Q<T']M7_ (*#>%/#/P&%KXKT+XB_"K]A;X#ZUKJZ-X$ETB[M=9\-6WQ0
M^(>I>)?%/B(MI5S:VDUSX0T+Q3JVKW=U&)O$7CB"1M0\,*[*U]5VNEJ+FE>U
MHOO9O3[T?U#Z#_P4\_9A\1_\%!O%7_!-#3C\4!^TAX/\%1^-M4N;KX:Z];?#
M&6U/AO3?&$VE6/CJ0"&?4;;PWJUAJ+W\FGP>%KBXF.A6'B.\\212Z.GZ'5_*
M=\/_ !QXTD_X.XOCGX-D\7>)G\(1?\$]=#CB\*OKNIMX<C2'3?A1K,2IHAN?
M[-41:OJ6HZI&1;;H[^_O+I");F9GL>"O^"U?_!3?]O?XI?&NQ_X)._\ !/7X
M5_$;]GSX$_$#Q!\+]:^-_P"TK\6H?!Z>,O%>A36_R:)X=L/$OA";13>V%Q#K
M%KI8NO%=S'H]]IUUK5WH-]<?V4%;MV3;;[W&I;W_ )FE97>GH?TJZ]\=?@CX
M6\42>!_$_P 8_A7X<\:1"S:7PAKWQ"\(Z1XHC74(DGL&D\/ZAJ]OJR"^ADCF
MLRUH!<Q.DD.]&!/J,<D<T<<T,B2Q2HDD4L;J\<D;J&22-U)5T=2&1U)5E(()
M!!K^%C]I_P#X)B?\%+_VS?BQXV^.7[1?_!$7_@G?XS^+GQ'CT:+QGX^TS]LW
MXU>#=7U1M T2P\-:1>K;^%/VB-.T>SO[+0=+TW3A=VVD[YX;&W>Z2XE5VD^,
MOV.?VB?VJ?A)_P &^O\ P6J^&MW\3_&_A/Q#^S%\>O"WP;\ V^G^.-4UK5?A
M!HOC+Q_X0\%_$OP!X'\:F\DU*'PU+!%K6E6CZ?>1P*NKZSJ6FFVN-5EF+MV?
M5+[Q<VMFGLVM^GJC_0*\0?M,?LX>$M5N]"\5?M _!+PSK=A*8;[1_$'Q6\":
M-JME,OWH;O3]2UZVN[>5>\<T*..XKH/ _P :_@U\3;N>P^&WQ;^&7Q!OK6+[
M1<V?@?Q[X5\67=M!G'G3V^@ZK?S0Q9X\R1%3/&[-?S5_\$_/^#=?_@D9\5?V
M(/V3/BW\3OV8KWQ]\2/BS^SM\'OB;X^\6^(/B]\84O\ 7?&/CSP%H/BGQ)J!
MM=$\<:/I%C;SZOJEVUI96&FVT%K;>5#B1U>:3\V_^"_O_!+3]B__ ()5_LZ_
MLZ?MA_\ !/[P!XM_9H_:$T+]K[X8>#M.\=>"OBS\3KV6/0]5\)_$3Q%=1-9>
M)_%.O0I<KJOA/1I(KFT-HSVJWVGWJWMC?S0 LKV3=]>BMI?S\@YI6O96WW=[
M?<?WBUPWCGXG_#3X86EA?_$OXA^!OAY8:K=/8Z7>^.?%N@>$K34KV.(SR6=A
M<Z_J&GPWETD"M,]O;O),L0,C($!-?A7_ ,% _P#@L1^T%\%OVK?A'_P3O_8-
M_9&@_:O_ &SOB9\*M(^,.LKXO\8V_@/X6_#_ ,&:BVHC[=JD\MSIDVL2QV^C
MWVI:J\WB?PKIVC6,^E1V]]KNK:@-(@_/?]LKX!_\%MO^"@FA^!O#?[8'_!(#
M_@G1\9-'^&NKZOKO@BWO/VI_B-X6DT+4]>LK73]8FAN_!OQX\/WES#J-K8V*
MW%I>S7%L9+*UF6-98E>E;OI^?W?\,-R[7?R=OO1_7MX9\6>%O&FDPZ]X.\2Z
M!XLT.Y++;ZSX9UG3M>TF=DQO6'4=+N;JSE*Y&X),Q7(SC-%?Y7'QD\1_\% ?
M^")?[:.H:%\.OAWX7_X)^:Y\9O@!IWBF]^#'P8^-7BSX[_"K6=#F\=S:5%XN
MW^/_ !?X^GLO$<FL>$+ZQ@BO=4NKW1K%;Z'2GLM+UV>WF*&DNO1/[_07.NJ:
M?]>A_>?_ ,%O_P!C.^_:K_9#OO%G@C1WU3XO?L[WE]\3/!MO:0&?5-<\,"S2
M+XC>$;%8TDGFFU+1+.T\0V-E;H]SJ.M>%-)TVW&^\(/\H?[&'QEET3Q#X=N#
M=F/[-?6D5T-^ ;9YHUD8X."%CRXSD J#7^BG7\>'_!5#_@EYK_[-'Q2UO]K'
M]G?0)K[X">,M7FUCXE^$-&MF>3X.^)-6N_,U#5K>QMU)3X:ZS>SM=P3P1?9O
M!]]--I5R+31)-%V?K?AIQ-1PM6609A.*H8J<_J;J22IRG77+7P4I2:C'V]W.
MA=I.JY4TU.=-2_D#Z5/A9B^(,G7'&04JG]JY)2I5<PEA82EB:-/ 36(P.<4X
M4TYU/[/G34,9RJ4HX3]]).C3KNG^D_\ P55\6ZQ\-_V=?@3J5K<2);^(/"T.
MD:G<R2-YPO[/2-(U"-V)Y:6Y&KZH[DOG,9<YV9K^7/X _ ?Q_P#\% ?VJ_!/
MP"\%->Q:1J6IG5_B%XJ@C\VV\%_#S2;B"7Q3XGNF?]P)XK:5--T.VF95U/Q)
MJ6CZ63&+WS$_JL_X+%>$KWXH_P#!+[1/&WA*PNM7U3PM=?!+QGH<&EH;B^O8
M/&D6G^ K>TL+2".6YU&2^G\>Z>L%C9HT]Q.(&C23R@C>[?\ !)S_ ()[:3^P
ME\ +?_A)[*QO/V@_BM;Z9XD^,?B!!%<3:5/Y+SZ-\-]+O5+AM%\%QW<\%W+;
MR/!K'B2XUC5D=[&72X+/3"<74LGX*="@H1S2>99MA(05N=U/K-2HL566CY,-
MA\2H035I5(PBEK.W-C?!7$<6>.T^(,SG5Q/#-'A?@S,8U)IJA"E#*<-AZN5X
M-MR7/F&99=+%XB47S1HU93D[0HW_ $I\#^"_#7PX\&>$_A]X,TNWT3PCX(\.
M:+X3\,:/:KMM],T'P]IUOI6DV,7<K;6-K!%O8EW*EW+.S$_CW_P6>_X)=?$?
M_@ISX=_9#T;X<_$[P3\-9OV=_P!ICP_\9?$TWC73M=OXM<\+V=H+34K'0AH<
M%P_]OPB-)+&TU 6>G7I=TN-5T[RU>3]K:^.],^,7CRZ_X* >-?V?IKVP/PQT
M3]COX7_&+3].72[==4C\>>*?C5\7O!6KWLFM _:I;";P_P"#]$@@TMA]G@N(
M+B[0^9<R ?D+E)R<Y-RE*3E*3=W*4FY2DV[MMN3;;U;;;U9_9,80A"-.$8PI
MPC&$(12C&$(1C"$(QBDHQA&$8QBDE&,8I)))+Z>\::!)XK\'>+/"T5TEE+XE
M\,Z]H$=Y)$9TM)-9TJZTY+IX5>-ID@:Y$K1+(AD"% ZD[A_-]^S=_P $;OV\
M/V3_ /@C?XZ_X)]_ +]L[P%\)/VE/$WQC\6>.[3XZ^#-$\51:$G@7Q1=Z/#J
M?@RTUFXTY?&/@_6M:TK25:Y\9>'-)EU;1))I-.T@R!VUBOVC\=_&/QWH/[<W
M[.?P+TV^T^/X<_$?]G_]I3X@>*M/ETRWFU*Z\3_#3Q9\ ])\)7-IJ[$7-C:V
MEEX^\2I>640,5^]S:R38:SBKY+^&W[1'QT\>_P#!2#]I+X+ZGXY^.-I\*_@U
M\6/ /A#PKX7\#_LZ^#M<^!\N@:W^R[\-?BMJUO\ %3X^7GAW4O$WAWQ1>>+_
M !?K$UI86FNZ,8K,^%;"%)4U5]Z3:_!_<-I/7R:[;VO^1_/Q^Q5_P;]?\%HO
M^"?FL^+_ !=^S-^V/^P#X<^(GCN]NKSQ/\5/&'P<UCXG?%&_COCOOM,@\>?$
M'X->(O$.F:3J%RTM]JFGZ5>64.KW\K7FJB]G2%XOTY\*?LQ_\'.EIXF\.7/B
MK_@I3^PGJ7ABWU_1[CQ'8V_[/$4ES>Z!!J%O)K%E;1VWP;T&:2:ZT];B&)(M
M:T>9I)%$6K:<Q%W#]??'7]I;X^Z=_P %-M"_9H\*^(OC_IWPCM?@%^SC\2+F
MR^!/[/7P[^*^C1>)_B7\<_COX)\57WQR\>^,;'4-7^'/@2X\-_#GP[;Z;>>'
M8[>YAM[;QCJ\=REUI\"M^Q%/F?9?<+D71R7I)GXM^&/^"8?Q(T+_ (+@_$;_
M (*G7'Q,\$7'PN\9_LOZ?\$;'X9PZ=KR^/K+Q-:V7@G3)M1NKQX?^$>?0C!X
M2EOHKF*^.H--?QV#Z6B6[:C-\!^'_P#@BA_P4H_83^(?QJOO^"1O_!13X?\
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M[>>)-6U75M3O+F*S12ON?XU_MJ^,_P!FO]H+XS?\-Q_M.:Q^Q+\%I_%R:/\
MLO>*+CX1_#[Q-^S;\3_ 4GASPS?V,T_QEU3P[XC\5V?[1@UNU\=OXE^%WB:]
M\'V,'A?3SJ_@OP_XKT?3+WQ9&4<S_I+_ "#ECVOYO5G[B56O;*SU*SN].U&T
MMK_3[^VGLKZQO8(KJSO;.ZB>"ZM+NUG22"YMKF"1X9X)D>*:)WCD1D8@E%+;
M5:-:IK1IK5--:IIZIK8;2:::333332::::::::::;33333:::;3X3X=Z)HR?
M#7P7HB:1IB:+IFAZ##IND+86BZ7I\.B?9I-&AL; 1"TM(M(DLK-],C@BC2P>
MTMFM!$T$13T2BBM*S;JU;MO]Y4>K;U<Y-O5O5O5O=O5MO4Y\'&,<)A5&,8I8
M7#12C&,4HQH4HQBE%)*,8I1C%)1BDE&,4DD5_%!_P<'_ !P^-7P5_P""K7[(
M[_!OXO\ Q1^$K^,OV</AKHOB]_AG\0/%G@-O%6C0?M,>-#!I/B1O"VK:4=<T
MR$WUZ8K#4S=6L9O+K9$/M$N\HK,Z3^DKXJ?\I1?V.?\ LTK]M+_U/?V4*K?L
M;_\ )W/_  58_P"SIO@G_P"L/_LS444 ?S:_\%Q_C=\9_@]_P7!_9.LOA)\7
M?B?\+;+Q[^SY^RMH?CFT^'/C[Q7X(M?&FBQ?M9_&V&+1_%EOX9U;3(O$>EQP
MZGJ44>GZPEY:)%J%]&L(2[N!)_;1110!_(O\"?BK\4/'W_!RI\4_A)XZ^)'C
M[QK\*?AGKWQS\5?#CX9>+?&'B'Q'\/?A_P")[/X$_"JPL_$?@CP7K&HWGAOP
MIKUK8^+O%=E;:QH.FV&H06GB?Q#;Q7"0ZUJ27/)?\',OQ/\ B5^S_P#'[]D/
MXA? ;XA^.?@EX^\??"3XZ>$O'?CCX1^+=?\ AMXP\:^%/!][X2UCPEX9\6^)
M?!NH:+K7B/P]X6U?Q'XAU3PYHNL7MYINB:CKVLWVF6UK<ZI?2SE% '[]_&V>
M>Z^.7_!*NYN9I;BYN/BQ\2I[BXGD>:>>>;]BOXX22S32R%I)999&9Y)'9G=V
M9F)8DU_-C_P6B^.OQN^$'_!<K]FO0OA-\8_BI\+]$^(7PO\ V.=,\?:/\._B
M%XN\$Z5XXTV']I/XM6,6G^+]/\-:OIEIXEL8K+5=4LX[36H;VW2UU*_MUC$5
MY<)(44 ?TI_$VRLM2_X*@?LSZ=J-I:ZAI]_^PK^VK97UA>V\5U9WMG=?&7]B
M^"ZM+NUG22"YMKF"22&X@F1XIHG>.1&1F4_+/_!)[PEX5\3?\$3?AQX&\2>&
M?#_B'P5J7P__ &J?"^H^#]<T;3=6\+7_ (:7XW_''3%\.WOA^_MKC2;K0ETV
M./3ETF>TDL!8QI:"W^SJL8** /S/_P"#7/X^?'7XQG]IC1_B[\:?BS\5-(\%
M>!O@I:^#M+^)'Q&\8>.-.\)6LVO?%>QEMO#-CXGUG5+;08);+2],LY(=*BM8
MWM=.L;=E,5I;I'X]_P $2?CE\:];_P""SW[=/P3UGXP?%+5_@SX7^('[>FI^
M&?A'J?Q \67_ ,,?#NI)^UO/*FH:%X"N]7E\*Z1?++JNJ2+=Z?I-O.LFI7[B
M0->7!D** /$OBMXAU_\ :'_X+ ?MK? 'X_ZYK'QR^!'P\\2?%[Q-\/\ X*?&
M'4[WXF_"3P-XCTV^_9YTK3O$'@[X<>-9];\'>&=;L-+\6^*]-LM5T71K*_M;
2#Q-XALX+B.WUK4H[DHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
